Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Accounts Payables: 2018-2025

Historic Accounts Payables for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Mar 2025 value amounting to $7.3 million.

  • China SXT Pharmaceuticals' Accounts Payables rose 468.01% to $7.3 million in Q1 2025 from the same period last year, while for Mar 2025 it was $7.3 million, marking a year-over-year increase of 468.01%. This contributed to the annual value of $7.3 million for FY2025, which is 468.01% up from last year.
  • China SXT Pharmaceuticals' Accounts Payables amounted to $7.3 million in FY2025, which was up 468.01% from $1.3 million recorded in FY2024.
  • In the past 5 years, China SXT Pharmaceuticals' Accounts Payables registered a high of $7.3 million during FY2025, and its lowest value of $1.3 million during FY2024.
  • Over the past 3 years, China SXT Pharmaceuticals' median Accounts Payables value was $1.4 million (recorded in 2023), while the average stood at $3.3 million.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Accounts Payables slumped by 60.96% in 2023, and later skyrocketed by 468.01% in 2025.
  • China SXT Pharmaceuticals' Accounts Payables (Yearly) stood at $3.0 million in 2021, then climbed by 15.84% to $3.5 million in 2022, then slumped by 60.96% to $1.4 million in 2023, then declined by 7.14% to $1.3 million in 2024, then soared by 468.01% to $7.3 million in 2025.